UK to identify barriers to commercialisation of regenerative medicines
This article was originally published in RAJ Devices
The UK government has launched a stock-taking exercise to gauge the latest developments in the field of regenerative medicine1. The aim is to identify barriers to commercialisation and clinical application and assess what actions the National Health Service should take to prepare for new treatments.
You may also be interested in...
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.